Foresite Capital, a San Francisco, CA-based growth equity firm focused on late-stage healthcare investing, recently closed its second fund at $300m.
Foresite Capital Fund II, which followed Foresite Capital Fund I, a $100m fund that closed in January 2013, focuses on backing transformative late stage companies across all healthcare sectors.
Led by Jim Tananbaum, founder and CEO, Dorothy Margolskee, Matt Buten and Christine Aylward and Dennis Ryan, the firm has already invested $57m in the Series DD financing of Intarcia Therapeutics, Inc., a biopharmaceutical company developing innovative therapies for Type II Diabetes (read here), and an $18m investment in a secondary purchase of Universal American (NYSE: UAM) at $6.03 a share.
Foresite also has an office in New York, NY.
FinSMEs
22/04/2014